Search | IOVS | ARVO Journals

Access Provided By:
MIT Libraries

Forgot password?

Create an Account

View

Showing 1 – 10 of 10

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract May 2006

Use of Pamidronate and Supplemental Saline to Reduce Toxicity and Increase Effectiveness of Calcitriol in a Retinoblastoma Model

A. Kulkarni; E.M. Gates; S.R. Darjatmoko; D.M. Albert

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):2811.

ARVO Annual Meeting Abstract May 2005

A Comparison of the Effectiveness of 1–Hydroxyvitamin D2 in Human Retinoblastoma and Neuroblastoma Xenograft Models

W.W. Yang; M.M. Marcet; S.R. Darjatmoko; S.A. Strugnell; M.J. Lindstrom; S.E. Linden; D.M. Albert

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):4256.

ARVO Annual Meeting Abstract May 2004

Efficacy of a Novel Vitamin D Analog (2–methylene–19–nor–(20S)–1a–hydroxybishomopregnacalciferol, DP006) for Treatment of Human Retinoblastoma in the LH Beta–Tag Mouse Model

C.M. Damico; L.A. Plum; S. Darjatmoko; J.M. Lokken; H.F. DeLuca; M. Clagett–Dame; D.M. Albert; A. Kumar

Invest. Ophthalmol. Vis. Sci.. 2004; 45(13):3361.

ARVO Annual Meeting Abstract May 2004

Transscleral delivery of a vitamin D analog in a heriditary murine model for the treatment of retinoblastoma

C. Hejny; S. Darjatmoko; M.J. Lindstrom; C. Damico; A. Kumar; D.M. Albert

Invest. Ophthalmol. Vis. Sci.. 2004; 45(13):3549.

ARVO Annual Meeting Abstract May 2004

Are Vitamin D Analogs Effective in Treating Large Tumors and for Prolonged Use in the Murine Retinoblastoma Models?

D.M. Albert; A. Kumar; S. Darjatmoko; S. Strugnell; S. Patel; C. Damico

Invest. Ophthalmol. Vis. Sci.. 2004; 45(13):3553.

ARVO Annual Meeting Abstract May 2004

Effectiveness of 1–hydroxyvitamin D2 (1–OH–D2) in Inhibiting Tumor Growth in the Tyr–Tag Transgenic Pigmented Ocular Tumor Model

A. Kumar; D.M. Albert; S. Darjatmoko; S. Strugnell; C.M. Damico

Invest. Ophthalmol. Vis. Sci.. 2004; 45(13):3578.

ARVO Annual Meeting Abstract May 2003

Histopathologic Characterization of Eyes Enucleated following Brachytherapy in the Collaborative Ocular Melanoma Study (COMS)

R.B. Avery; D.M. Albert; W.R. Green; H.E. Grossniklaus; M. Diener-West

Invest. Ophthalmol. Vis. Sci.. 2003; 44(13):1555.

ARVO Annual Meeting Abstract May 2003

Tumor Inhibition and Toxicity Studies of 1alpha-Hydroxyvitamin D2 and 1,25-Dihydroxy-16-ene-23-yne-Vitamin D3 in a Retinoblastoma Xenograft Model With Large Tumors

D.M. Albert; M.L. Zimbric; D.G. Dawson; J. Gleiser; S.R. Darjatmoko; J.M. Lokken; S.M. Patel; M.J. Lindstrom

Invest. Ophthalmol. Vis. Sci.. 2003; 44(13):1582.

ARVO Annual Meeting Abstract May 2003

p21Waf1/Cip1 and p53 Gene Therapy in a Mouse Model of Retinoblastoma

I.S. Audo; S.R. Darjatmoko; J.M. Lokken; M.J. Lindstrom; B.A. Faha; C.L. Schlamp; D.M. Albert; R.W. Nickells

Invest. Ophthalmol. Vis. Sci.. 2003; 44(13):1585.

ARVO Annual Meeting Abstract May 2003

26-Week Intravitreal Injection Toxicity Study with rhuFab Vegf in Cynomolgus Monkeys with an 8-Week Recovery

C.A. O'Neill; P.E. Miller; B.J. Christian; J.C. Beyer; E. Bentley; J.N. VerHoeve; T.M. Nork; R.A. Leedle; R.R. Dubielzig; D.M. Albert

Invest. Ophthalmol. Vis. Sci.. 2003; 44(13):3929.

Advertisement